A clinical trial with IDIBELL participation confirms the benefits of a new drug in heart failure
Dapagliflozin significantly reduces the risk of cardiovascular death and hospitalizations for heart failure (HF).
August 2022
A new endometrial cancer screening test that can be done at home
It is an epigenetic test capable of detecting between 90 and 100% of cases of endometrial cancer. This new rapid and non-invasive method can be performed: on cervical cytology samples obtained in the doctor’s office, and on vaginal self-samples collected at home.
Early physical therapy in patients with severe COVID-19 can reduce hospitalization days
A retrospective study by IDIBELL and the Bellvitge University Hospital shows that starting physical rehabilitation of patients admitted to the UCRI with severe COVID-19 before seven days reduces hospitalization time.
An incidental finding in prostate biopsies allows the diagnosis of a previously unsuspected systemic disease
The research, led by researchers from IDIBELL and the Bellvitge University Hospital (HUB), has established that when amyloidosis is detected in the prostate, it is almost always the TTR-type systemic variant of the disease associated with aging.
Tobacco control in the 21st century: A global and local perspective
Among recent achievements, first of all, the entry into force of the WHO Framework Convention on Tobacco Control in 2005 stands out, which has surely been the most important milestone, not only for tobacco control, but as a paradigm of public health on a global scale.
Five IDIBELL researchers star in the Women of Science section of the television program Aula L’H
The Aula L’H program on L’Hospitalet digital television, specialized in education, together with the Institut Bellvitge and IDIBELL, have carried out, throughout the 2021-22 academic year, a complete edition of the Women of Science section, entirely dedicated to disseminating the research work, the research career and the personality of five IDIBELL scientists.
Validated a tool that assesses the risk of sudden death due to a heart disease
Twenty-nine reference centers from the United States, Canada, the Netherlands, Italy, France, and Spain, including IDIBELL, have participated in an international multicenter study that validated a model for predicting the risk of ventricular arrhythmias and sudden death in arrhythmogenic cardiomyopathy of the right ventricle (ARVC).
A study of IDIBELL and IDIBGI evaluates the efficacy of an anti-tumour drug against obesity
The drug inhibits the S6K1 protein, which is essential for the development of new fat cells, responsible for the disproportionate growth of fat deposits in obese people.